Could Vaccination Against
            <i>Neisseria Gonorrhoeae</i>
            be on the Horizon?

Russell, Michael W.

doi:10.2217/fmb-2017-0262

Cited by 6 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current comprehensive effort to provide gonorrhea vaccine led by the National Institute of Health (NIH) and World Health Organization (WHO), as well as many public health agencies worldwide, demonstrate the dire need for this vaccine. The continuous global research to understand the mechanisms of host–pathogen interactions would help unravel the mechanism of immune responses against gonococcal infections that help design refined vaccines [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Novel Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticles as Vaccine Formulation in Microneedle-Based Transdermal Immunization

et al. 2018

View full text Add to dashboard Cite

Neisseria gonorrhoeae is a strict human pathogen responsible for more than 100 million new sexually transmitted infections worldwide each year. Due to the global emergence of antibiotic resistance, the Center for Disease control (CDC) recently listed N. gonorrhoeae as an urgent threat to public health. No vaccine is available in spite of the huge disease burden and the possibility of untreatable gonorrhea. The aim of this study is to investigate the immunogenicity of a novel whole-cell-based inactivated gonococcal microparticle vaccine formulation loaded in dissolvable microneedles for transdermal administration. The nanotechnology-based vaccine formulation consists of inactivated whole-cell gonococci strain CDC-F62, spray dried and encapsulated into biodegradable cross-linked albumin matrix with sustained slow antigen release. The dry vaccine nanoparticles were then loaded in a dissolvable microneedle skin patch for transdermal delivery. The efficacy of the whole-cell microparticles vaccine formulation loaded in microneedles was assessed in vitro using dendritic cells and macrophages as well as in vivo mouse model. Antibody titers were measured using an enzyme immunosorbent assay (ELISA) and antigen-specific T lymphocytes were assessed in spleens and lymph nodes. Here we report that whole-cell-based gonococcal microparticle vaccine loaded in dissolvable microneedles for transdermal administration induced significant increase in antigen-specific IgG antibody titers and antigen-specific CD4 and CD8 T lymphocytes in mice compared to gonococcal antigens in solution or empty microneedles. Significant increase in antigen-specific IgG antibody levels was observed at the end of week 2 in groups that received the vaccine compared to the group receiving empty nanoparticles. The advantages of using formalin-fixed whole-cell gonococci that all immunogenic epitopes are covered and preserved from degradation. The spherical shaped micro and nanoparticles are biological mimics of gonococci, therefore present to the immune system as invaders but without the ability to suppress adaptive immunity. In conclusion, the transdermal delivery of microparticles vaccine via a microneedle patch was shown to be an effective system for vaccine delivery. The novel gonorrhea nanovaccine is cheap to produce in a stable dry powder and can be delivered in microneedle skin patch obviating the need for needle use or the cold chain.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticles as Vaccine Formulation in Microneedle-Based Transdermal Immunization

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In the 1970s, a crude, killed whole-cell vaccine was successful in developing an antibody response but failed to induce an adaptive immune response in clinical trials [ 132 , 133 ]. Another vaccine utilized the gonococcal pilin, but failed in a large field trial and heterologous challenge study, attributed to the antigenic variation of the pili [ 134 – 136 ]. A third unsuccessful attempt focused on the porin protein, also attributed due to genetic variation [ 134 ].…”

Section: Vaccine Development For N Gonorrhoeaementioning

confidence: 99%

“…Another vaccine utilized the gonococcal pilin, but failed in a large field trial and heterologous challenge study, attributed to the antigenic variation of the pili [ 134 – 136 ]. A third unsuccessful attempt focused on the porin protein, also attributed due to genetic variation [ 134 ]. In general, vaccine development is impeded by the lack of natural acquired immunity that can be developed to N. gonorrhoeae due to its diverse antigenic variation and multiple mechanisms of immune evasion and its host restriction to humans [ 137 , 138 ].…”

Section: Vaccine Development For N Gonorrhoeaementioning

confidence: 99%

Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions

Lin

Adamson

Klausner

2021

Drugs

View full text Add to dashboard Cite

Neisseria gonorrhoeae is the second most common bacterial sexually transmitted infection in the world after Chlamydia trachomatis . The pathogen has developed resistance to every antibiotic currently approved for treatment, and multidrug-resistant strains have been identified globally. The current treatment recommended by the World Health Organization is ceftriaxone and azithromycin dual therapy. However, resistance to azithromycin and ceftriaxone are increasing and treatment failures have been reported. As a result, there is a critical need to develop novel strategies for mitigating the spread of antimicrobial-resistant N. gonorrhoeae through improved diagnosis and treatment of resistant infections. Strategies that are currently being pursued include developing molecular assays to predict resistance, utilizing higher doses of ceftriaxone, repurposing older antibiotics, and developing newer agents. In addition, efforts to discover a vaccine for N. gonorrhoeae have been reignited in recent years with the cross-protectivity provided by the N. meningitidis vaccine, with several new strategies and targets. Despite the significant progress that has been made, there is still much work ahead to combat antimicrobial-resistant N. gonorrhoeae globally.

show abstract

“…A further highly popular article was an Editorial entitled "Could vaccination against Neisseria gonorrhoeae be on the horizon?" written by Michael W Russell [4], which discusses the continued threat of Gonorrhea and considers recent developments both in improved vaccine testing and in further understanding of its pathogenicity, with a forward positive outlook for the future.…”

Section: Content Highlightsmentioning

confidence: 99%

Welcome to the 14 ^th Volume of Future Microbiology

Colvin

2018

Future Microbiol.

View full text Add to dashboard Cite

Could Vaccination Against Neisseria Gonorrhoeae be on the Horizon?

Cited by 6 publications

References 17 publications

Novel Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticles as Vaccine Formulation in Microneedle-Based Transdermal Immunization

Novel Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticles as Vaccine Formulation in Microneedle-Based Transdermal Immunization

Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions

Welcome to the 14 ^th Volume of Future Microbiology

Contact Info

Product

Resources

About

Could Vaccination Against Neisseria Gonorrhoeae be on the Horizon?

Cited by 6 publications

References 17 publications

Novel Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticles as Vaccine Formulation in Microneedle-Based Transdermal Immunization

Novel Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticles as Vaccine Formulation in Microneedle-Based Transdermal Immunization

Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions

Welcome to the 14 th Volume of Future Microbiology

Contact Info

Product

Resources

About

Welcome to the 14 ^th Volume of Future Microbiology